查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2006362

抗菌藥物敏感性測試市場：按產品類型、測試類型、方法、應用和最終用戶分類－2026-2032年全球市場預測

Antimicrobial Susceptibility Testing Market by Product Type, Test Type, Method, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，抗菌藥物敏感性測試市場價值將達到 42.5 億美元，到 2026 年將成長至 45 億美元，到 2032 年將達到 64.3 億美元，複合年成長率為 6.07%。

主要市場統計數據
基準年 2025 42.5億美元
預計年份：2026年 45億美元
預測年份 2032 64.3億美元
複合年成長率 (%) 6.07%

簡明策略概述，概述抗菌藥物敏感性測試的趨勢、營運挑戰和診斷技術創新，以指導臨床實踐和研發 (R&D) 中的決策。

抗菌藥物敏感性檢測是臨床微生物學和治療管理的基礎，影響全球的治療策略、監測活動和藥物開發平臺。本執行摘要整合了當前該領域的交叉趨勢、技術轉折點、監管壓力和運營挑戰，旨在為檢查室、醫療保健系統、藥物研發和公共衛生領域的領導者提供簡潔明了、基於證據的概述，幫助他們調整自身能力以滿足不斷變化的臨床和商業性需求。

自動化、分子診斷、勞動力短缺和整合服務如何重塑檢查室領域的實驗室工作流程和供應商關係。

近年來，支撐診斷技術、檢查室操作和合理使用抗生素的整個生態系統都發生了變革性變化。自動化技術已從獨立的分析儀器發展成為集自動化​​系統、盤式分析儀和互聯資料管道於一體的完全整合平台。這種轉變不僅減少了人工勞動，還提高了可重複性和資料完整性，使大規模機構能夠在保證品質的前提下擴大檢測能力。同時，基因分型和分子檢測技術的進步提供了對傳統表現型檢測的補充訊息，加速了抗藥性決定因素的識別，並指南了精準醫療的發展。

我們將評估貿易政策對診斷設備採購、試劑持續供應以及在不斷變化的關稅環境下籌集資金等方面的選擇所產生的累積影響。

政策變化，例如關稅和跨境貿易成本的調整，會對診斷供應鏈和籌資策略產生連鎖反應，進而影響設備供應、試劑供應和價格走勢。進口診斷組件和成品設備的關稅上漲將導致檢查室和製造商面臨更高的接收成本，通常需要重新評估供應商合約和庫存策略。有些機構會加快在擁有合格供應商的地區進行在地採購，而有些機構則會協商長期供應合約以規避貿易波動風險。此外，關稅上漲可能會影響資本投資決策的步伐，促使買家延長設備使用壽命或優先考慮模組化升級而非平台更換。

透過整合產品、測試、方法、應用和最終用戶觀點進行細分分析，可以揭示創新和商業化的優先目標。

了解產品、測試、方法、應用和最終用戶等細分領域之間的交集，對於協調研發重點、籌資策略和商業化計劃至關重要。依產品類型分類，市場涵蓋儀器、試劑盒和服務。儀器包括自動化系統和手動儀器，其中自動化系統又細分為自動分析儀和自動盤式分析儀。試劑盒分為抗生素敏感性測試試劑盒和微生物鑑定試劑盒，而服務則涵蓋分析測試服務和客製化測試解決方案。這種產品層面的區分凸顯了自動化投資與試劑組合或外包服務投資相比，對耗材消耗、供應商鎖定和工作流程重新設計的影響各不相同。

美洲、歐洲、中東和非洲以及亞太地區診斷技術和供應鏈策略的採用情況，為制定適合各地區的商業性方法提供了重要的見解。

區域趨勢塑造著需求模式和供應鏈策略，因此，在全球規劃中，了解這些細微的區域差異至關重要。在美洲，需求主要大規模醫院網路、先進的臨床檢查室以及對合理使用抗生素的高度重視所驅動，而這又與支付方和監管機構的期望密切相關，進而推動了自動化和互聯診斷平台的普及。供應鏈的韌性始終是人們關注的焦點，這促使企業制定本地庫存策略，並建立長期的供應商關係，以確保試劑和耗材的穩定供應。在歐洲、中東和非洲，監管的多樣性和資源的差異導致了不同的應用普及率。雖然歐洲市場的一些領先實驗室優先考慮先進的分子診斷和自動化表現型分析工作流程，但該地區的其他一些實驗室則更注重成本效益高且穩健的方法，這些方法即使在基礎設施有限的環境中也能大規模部署。

設備供應商、試劑專家和服務供應商之間的競爭與合作策略正在塑造平台整合和經常性收入模式。

競爭格局由成熟的診斷設備製造商、專業試劑供應商以及提供分析檢測和客製化解決方案的服務供應商組成。現有設備供應商持續投資於平台整合、軟體驅動的決策支援和互通性，以維持其在臨床檢測領域的地位。同時，小規模、更靈活的公司正在開發針對特定抗藥性機制的基因分型檢測和專用試劑組，這為與尋求拓展檢測業務的大型公司建立合作關係創造了機會。服務供應商透過提供端到端的驗證支援、遠端設備監控以及旨在滿足監管申報要求的客製化檢測方案來脫穎而出。

為經營團隊提供切實可行的建議，以增強韌性、加快自動化採用，並建立符合使用者需求的差異化產品和服務結構。

領導者必須採取積極主動的措施來抓住機會並降低風險。首先，應優先投資於自動化和可互通的軟體，以減少人工工作量、提高可重複性，並實現臨床和研究環境中的可擴展測試。其次，應實現供應鏈多元化，認證關鍵試劑和耗材的替代供應商，並建立合約機制，即使在供應中斷期間也能靈活承諾數量並優先供應。此外，還應加強診斷開發人員和最終用戶之間的合​​作，共同設計檢驗研究和服務模式，以應對實際檢查室中的各種限制和監管要求。

為確保實際相關性和方法論的嚴謹性，採用了穩健的混合方法研究方法，結合了初次訪談、技術檢驗和第二手資料。

本調查方法採用多層次調查方法，整合了初步訪談、對二手資訊的嚴格檢驗以及技術檢驗練習。初步數據透過實驗室經理、採購經理、診斷試劑開發人員和服務供應商的結構化訪談收集，以了解營運重點、採購因素和創新藍圖。二手研究整合了同行評審文獻、監管指南和技術白皮書，以檢驗定性和定量檢測方法之間的差異，並了解自動化分析儀、自動盤式分析儀和分子檢測技術的性能標準演變。

為實現先進藥敏試驗的臨床和公共衛生效益，對技術、營運和商業性策略進行總結。

抗菌藥物敏感性檢測正處於轉折點，技術創新、營運壓力和政策趨勢的融合正在重塑診斷實踐。自動化、互補基因分型方法和數據驅動的合理應用工具的持續進步有望提高診斷速度和臨床決策水平，同時也對檢驗、互通性和人力資源能力提出了新的要求。供應鏈的韌性和靈活的商業模式預計將影響檢查室和研究機構採用新平台和檢測方法的速度。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：抗菌藥物敏感性測試市場：依產品類型分類

  • 裝置
    • 自動化系統
      • 自動分析儀
      • 自動盤式分析儀
    • 手動設備
  • 試劑和試劑盒
    • 抗菌藥物敏感性測試試劑盒
    • 微生物鑑定試劑盒
  • 服務
    • 分析測試服務
    • 客製化檢測解決方案

第9章：按檢測類型分類的抗菌藥物敏感性檢測市場

  • 抗菌藥物敏感性試驗
  • 抗真菌藥物敏感性試驗
  • 抗寄生蟲藥物敏感性試驗
  • 抗病毒藥物敏感性試驗

第10章：抗菌藥物敏感性測試市場：依方法分類

  • 定性方法
    • 瓊脂稀釋法
    • 自動AST
    • 紙錠擴散法
    • 基因分型
  • 定量方法
    • 肉湯大稀釋法
    • Etest 方法

第11章：抗菌藥物敏感性測試市場：按應用領域分類

  • 臨床診斷
  • 藥物發現與開發
  • 流行病學

第12章：抗菌藥物敏感性測試市場：依最終用戶分類

  • 學術和政府附屬研究機構
  • 醫院和診斷中心
  • 製藥和生物技術公司

第13章：抗菌藥物敏感性檢測市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：抗菌藥物敏感性測試市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 抗菌藥物敏感性檢測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國抗菌藥物敏感性檢測市場

第17章：中國抗菌藥物敏感性檢測市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Accelerate Diagnostics, Inc.
  • Alifax Srl
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • BIOANALYSE TIbbi Malz. San. ve Tic. Ltd. Sti.
  • Biological Safety Solutions Ltd/Oy
  • BioMerieux SA
  • Bruker Corporation
  • Creative Diagnostics
  • Danaher Corporation
  • Erba Lachema sro
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche AG
  • Himedia Laboratories Private Limited
  • INTEGRA Biosciences AG
  • Laboratorios Conda, SA
  • Launch Diagnostics Limited
  • Leading Biology, Inc.
  • Liofilchem Srl
  • Mast Group Ltd.
  • MP Biomedicals, LLC
  • Pfizer Inc.
  • Qiagen NV
  • QuantaMatrix Inc.
  • Resistell AG
  • Synoptics Group
  • Thermo Fisher Scientific Inc.
  • Zhuhai DL Biotech Co., Ltd.
Product Code: MRR-464C422F4BD3

The Antimicrobial Susceptibility Testing Market was valued at USD 4.25 billion in 2025 and is projected to grow to USD 4.50 billion in 2026, with a CAGR of 6.07%, reaching USD 6.43 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.25 billion
Estimated Year [2026] USD 4.50 billion
Forecast Year [2032] USD 6.43 billion
CAGR (%) 6.07%

A concise strategic introduction framing antimicrobial susceptibility testing trends, operational imperatives, and diagnostic innovation that guide clinical and R&D decision-making

Antimicrobial susceptibility testing is a cornerstone of clinical microbiology and therapeutic stewardship, influencing treatment decisions, surveillance activities, and drug development pipelines worldwide. This executive summary synthesizes cross-cutting trends, technological inflection points, regulatory pressures, and operational imperatives shaping the field today. It aims to provide a concise, evidence-based briefing for leaders in laboratories, health systems, pharmaceutical development, and public health who must align capabilities with evolving clinical and commercial demands.

The landscape is defined by the convergence of automation, molecular diagnostics, and data-driven decision support. Faster time-to-result and improved reproducibility are driving investment in automated instruments and integrated workflows, while genotypic approaches complement phenotypic assays to give clinicians a richer understanding of resistance mechanisms. At the same time, regulatory scrutiny of diagnostic performance, reimbursement dynamics, and supply chain resiliency continue to affect implementation timelines and capital allocation. This introduction frames the topics addressed in the following sections and sets expectations for actionable insights that follow, positioning readers to evaluate strategic options in procurement, laboratory modernization, and collaborative research.

How automation, molecular diagnostics, workforce constraints, and integrated services are reshaping laboratory workflows and supplier relationships in diagnostics

Recent years have ushered in transformative shifts across diagnostic technology, laboratory operations, and the broader ecosystem that supports antimicrobial stewardship. Automation has moved beyond stand-alone analyzers toward fully integrated platforms that combine automated systems, plate readers, and connected data pipelines. This change not only reduces hands-on time but also elevates reproducibility and data integrity, enabling larger institutions to scale testing capacity while maintaining quality. Simultaneously, advances in genotypic methods and molecular panels are providing complementary insights to traditional phenotypic assays, accelerating identification of resistance determinants and informing precision therapy.

Workforce dynamics and laboratory consolidation are forcing organizations to rethink workflows; shortages of skilled technicians increase the value of automation and remote monitoring capabilities. Reagents and kits are evolving too, with manufacturers optimizing formulations for stability and compatibility with automated analyzers and automated plate readers to reduce variability and logistical burden. Services are expanding beyond routine analytical testing to offer custom testing solutions and advisory support for assay validation and regulatory submissions. Taken together, these forces are reshaping procurement priorities, vendor relationships, and the structure of diagnostic service offerings, prompting stakeholders to prioritize agile, interoperable solutions that support both clinical diagnostics and drug development pathways.

Evaluating cumulative trade policy impacts on diagnostic sourcing, reagent continuity, and capital procurement choices amid changing tariff environments

Policy shifts that alter duties and cross-border trade costs can ripple through diagnostic supply chains and procurement strategies, influencing instrument sourcing, reagent availability, and pricing dynamics. When tariffs increase on imported diagnostic components or finished instruments, laboratories and manufacturers face higher landed costs that often require re-evaluation of supplier contracts and inventory strategies. Some organizations respond by accelerating local sourcing where capable suppliers exist, while others negotiate long-term supply agreements to hedge exposure to trade volatility. In addition, higher tariffs can affect the cadence of capital investment decisions, prompting buyers to extend equipment lifecycles or prioritize modular upgrades over full platform replacements.

Beyond direct cost effects, tariff changes can create secondary impacts on innovation diffusion and service delivery. Manufacturers with geographically diversified production footprints may reallocate manufacturing to regions with preferential trade terms, which can alter lead times and qualification requirements for regulatory filings. Service providers that perform analytical testing and custom testing solutions may need to adjust pricing or revise cross-border service agreements to maintain margins. For clinical entities and research organizations, the pragmatic response often combines inventory buffering, supplier diversification, and closer collaboration with vendors to secure continuity of reagents and critical consumables. Ultimately, the cumulative effects of tariff shifts emphasize the importance of resilient sourcing strategies, contractual flexibility, and scenario planning to manage supply chain risk while sustaining diagnostic quality and operational continuity.

Integrated segmentation analysis that aligns product, test, method, application, and end-user perspectives to reveal priority targets for innovation and commercialization

Understanding how product, test, method, application, and end-user segments intersect is essential to aligning R&D priorities, procurement strategies, and commercialization plans. Based on product type, the landscape spans instruments, reagents and kits, and services; instruments include automated systems and manual instruments, with automated systems further differentiated into automated analyzers and automated plate readers; reagents and kits divide into antibiotic susceptibility kits and microbial identification kits; and services encompass analytical testing services and custom testing solutions. This product-level distinction underscores that investments in automation will carry different implications for consumable consumption, vendor lock-in, and workflow redesign than investments in reagent portfolios or outsourced services.

Test type segmentation reflects clinical and research needs across antibacterial susceptibility testing, antifungal susceptibility testing, antiparasitic susceptibility testing, and antiviral susceptibility testing, each with distinct methodological requirements and clinical urgency. Method segmentation separates qualitative and quantitative approaches; qualitative methods include agar dilution, automated AST, disk diffusion, and genotypic methods, while quantitative methods comprise broth macrodilution and the Etest method. These methodological differences influence laboratory throughput, interpretive complexity, and regulatory validation pathways. Application segmentation shows demand centers in clinical diagnostics, drug discovery and development, and epidemiology, which in turn shape acceptance criteria and data deliverables. Finally, end-user segmentation identifies academic and government research institutes, hospitals and diagnostic centers, and pharmaceutical and biotechnology companies as primary consumers, each with unique procurement cycles, performance expectations, and budgetary constraints. Combining these lenses reveals where innovation will be most valuable, which channels require targeted commercial strategies, and how validation and service models should be configured to meet user needs.

Regional diagnostic adoption and supply chain strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific that inform tailored commercial approaches

Regional dynamics shape both demand patterns and supply chain strategies, and a nuanced view across geographies is critical for global planning. In the Americas, demand is driven by large hospital networks, advanced clinical laboratories, and a strong emphasis on antimicrobial stewardship tied to payer and regulatory expectations, which favors adoption of automation and connected diagnostic platforms. Supply chain resilience is a recurring concern, motivating local inventory strategies and longer-term supplier relationships to ensure steady access to reagents and consumables. Across Europe, Middle East & Africa, regulatory heterogeneity and resource variability create differentiated adoption trajectories; leading laboratories in some European markets prioritize advanced molecular and automated phenotypic workflows, while parts of the broader region focus on cost-effective, robust methods that can be deployed at scale with constrained infrastructure.

Asia-Pacific presents a mixed picture of rapid capacity expansion, significant public health-driven surveillance programs, and growing domestic manufacturing capabilities for reagents and instruments. Investment in laboratory infrastructure and public health surveillance is increasing in many markets, bolstering demand for both automated systems and analytical testing services. These regional contrasts mean that product design, commercial models, and partnership strategies must be tailored; solutions that succeed in one geography may need adaptation in pricing, service delivery, and regulatory support to achieve traction elsewhere. Cross-border collaboration and strategic regional partnerships can help bridge capability gaps, accelerate technology transfer, and align supply networks with regional priorities.

Competitive dynamics and partnership strategies among instrument vendors, reagent specialists, and service providers shaping platform integration and recurring revenue models

The competitive landscape is being shaped by a mix of established diagnostic manufacturers, specialized reagent suppliers, and service providers offering analytical testing and custom solutions. Incumbent instrument vendors continue to invest in platform integration, software-enabled decision support, and interoperability to maintain clinical laboratory relevance. At the same time, smaller and more agile firms are advancing genotypic assays and niche reagent kits that address specific resistance mechanisms, enabling partnership opportunities with larger firms seeking to broaden their test menus. Service providers are differentiating by offering end-to-end validation support, remote instrument monitoring, and customized testing panels designed to meet regulatory submission needs.

Strategic behavior includes forming alliances to accelerate market entry, pursuing acquisitions to fill portfolio gaps, and expanding service capabilities to capture recurring revenue from consumables and testing contracts. Manufacturers are also investing in digital tools that aggregate susceptibility data for local surveillance and stewardship programs, creating stickiness and value beyond the instrument sale. For pharmaceutical and biotechnology companies, collaborations with diagnostic developers and contract service providers are increasingly important to de-risk antimicrobial drug development through integrated testing strategies. Overall, competitive advantage accrues to organizations that combine technical excellence with adaptable commercial models, robust supply chains, and strong customer support frameworks.

Actionable recommendations for executives to strengthen resilience, accelerate automation adoption, and build differentiated product and service offerings aligned with user needs

Leaders must act deliberately to capture opportunities and mitigate risk. First, prioritize investments in automation and interoperable software that reduce manual workload, improve reproducibility, and enable scalable testing across clinical and research settings. Next, diversify supply chains and qualify alternate suppliers for key reagents and consumables, and establish contractual mechanisms that allow flexible volume commitments and priority fulfillment during supply disruptions. Strengthen collaboration between diagnostic developers and end users by co-designing validation studies and service models that address real-world laboratory constraints and regulatory expectations.

Additionally, invest in workforce development to close skill gaps through targeted training programs, remote monitoring tools, and workflow redesign that optimize the use of scarce specialist talent. For companies commercializing tests or instruments, adopt flexible pricing and service bundles that reflect the needs of distinct end users such as academic research centers, hospital systems, and pharmaceutical development teams. Finally, integrate surveillance data products and stewardship support into offerings to create differentiated value, foster long-term customer relationships, and demonstrate public health impact. These steps create a pragmatic roadmap to balance short-term resilience with long-term growth and innovation.

Robust mixed-methods research approach combining primary interviews, technical validation, and secondary evidence to ensure practical relevance and methodological rigor

The research approach combines a layered methodology that integrates primary interviews, rigorous secondary source triangulation, and technical validation exercises. Primary data was collected through structured interviews with laboratory directors, procurement leads, diagnostic developers, and service providers to capture operational priorities, procurement drivers, and innovation roadmaps. Secondary research synthesized peer-reviewed literature, regulatory guidance, and technical white papers to validate methodological distinctions across qualitative and quantitative testing approaches and to understand evolving performance standards for automated analyzers, automated plate readers, and molecular assays.

Technical validation involved cross-referencing method characteristics-such as throughput, time-to-result, and interpretive complexity-against documented laboratory workflows and published performance evaluations for genotypic and phenotypic methods. Supply chain and policy analyses incorporated trade data and public procurement patterns to assess vulnerability points and potential mitigation strategies. Throughout, findings were iteratively reviewed with subject matter experts to ensure accuracy and practical relevance. This mixed-methods design ensures that conclusions are grounded in real-world practice while reflecting the technical nuances of assay development, instrument integration, and service delivery.

Concluding perspective on aligning technological, operational, and commercial strategies to realize the clinical and public health benefits of advanced susceptibility testing

Antimicrobial susceptibility testing is at an inflection point where technological innovation, operational pressures, and policy dynamics converge to reshape diagnostic practice. The continued push toward automation, complementary genotypic methods, and data-enabled stewardship tools promises to improve diagnostic speed and clinical decision-making, while also introducing new requirements for validation, interoperability, and workforce competencies. Supply chain resilience and adaptable commercial models will influence how quickly laboratories and research organizations can adopt new platforms and assays.

Stakeholders that align investment with clear use-case prioritization-distinguishing the needs of clinical diagnostics, drug discovery and development, and epidemiology-will capture the greatest value. By integrating product-level strategies, regional tailoring, and partnerships that bridge technical and commercial gaps, organizations can both mitigate near-term risks and position themselves for sustained impact. The path forward favors pragmatic innovation that is interoperable, validated in real-world settings, and supported by service models that address the full lifecycle of instruments, reagents, and testing programs.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antimicrobial Susceptibility Testing Market, by Product Type

  • 8.1. Instruments
    • 8.1.1. Automated Systems
      • 8.1.1.1. Automated Analyzers
      • 8.1.1.2. Automated Plate Readers
    • 8.1.2. Manual Instruments
  • 8.2. Reagents & Kits
    • 8.2.1. Antibiotic Susceptibility Kits
    • 8.2.2. Microbial Identification Kits
  • 8.3. Services
    • 8.3.1. Analytical Testing Services
    • 8.3.2. Custom Testing Solutions

9. Antimicrobial Susceptibility Testing Market, by Test Type

  • 9.1. Antibacterial Susceptibility Testing
  • 9.2. Antifungal Susceptibility Testing
  • 9.3. Antiparasitic Susceptibility Testing
  • 9.4. Antiviral Susceptibility Testing

10. Antimicrobial Susceptibility Testing Market, by Method

  • 10.1. Qualitative Methods
    • 10.1.1. Agar Dilution
    • 10.1.2. Automated Ast
    • 10.1.3. Disk Diffusion
    • 10.1.4. Genotypic Method
  • 10.2. Quantitative Methods
    • 10.2.1. Broth Macrodilution
    • 10.2.2. Etest Method

11. Antimicrobial Susceptibility Testing Market, by Application

  • 11.1. Clinical Diagnostics
  • 11.2. Drug Discovery & Development
  • 11.3. Epidemiology

12. Antimicrobial Susceptibility Testing Market, by End User

  • 12.1. Academic & Government Research Institutes
  • 12.2. Hospitals & Diagnostic Centers
  • 12.3. Pharmaceutical & Biotechnology Companies

13. Antimicrobial Susceptibility Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Antimicrobial Susceptibility Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Antimicrobial Susceptibility Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Antimicrobial Susceptibility Testing Market

17. China Antimicrobial Susceptibility Testing Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Accelerate Diagnostics, Inc.
  • 18.6. Alifax S.r.l.
  • 18.7. Becton, Dickinson and Company
  • 18.8. Bio-Rad Laboratories, Inc.
  • 18.9. BIOANALYSE TIbbi Malz. San. ve Tic. Ltd. Sti.
  • 18.10. Biological Safety Solutions Ltd/Oy
  • 18.11. BioMerieux SA
  • 18.12. Bruker Corporation
  • 18.13. Creative Diagnostics
  • 18.14. Danaher Corporation
  • 18.15. Erba Lachema s.r.o.
  • 18.16. Eurofins Scientific SE
  • 18.17. F. Hoffmann-La Roche AG
  • 18.18. Himedia Laboratories Private Limited
  • 18.19. INTEGRA Biosciences AG
  • 18.20. Laboratorios Conda, S.A.
  • 18.21. Launch Diagnostics Limited
  • 18.22. Leading Biology, Inc.
  • 18.23. Liofilchem S.r.l.
  • 18.24. Mast Group Ltd.
  • 18.25. MP Biomedicals, LLC
  • 18.26. Pfizer Inc.
  • 18.27. Qiagen N.V.
  • 18.28. QuantaMatrix Inc.
  • 18.29. Resistell AG
  • 18.30. Synoptics Group
  • 18.31. Thermo Fisher Scientific Inc.
  • 18.32. Zhuhai DL Biotech Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED PLATE READERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED PLATE READERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED PLATE READERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIBIOTIC SUSCEPTIBILITY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIBIOTIC SUSCEPTIBILITY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIBIOTIC SUSCEPTIBILITY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROBIAL IDENTIFICATION KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROBIAL IDENTIFICATION KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROBIAL IDENTIFICATION KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANALYTICAL TESTING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANALYTICAL TESTING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANALYTICAL TESTING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CUSTOM TESTING SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CUSTOM TESTING SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CUSTOM TESTING SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIBACTERIAL SUSCEPTIBILITY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIBACTERIAL SUSCEPTIBILITY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIBACTERIAL SUSCEPTIBILITY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIFUNGAL SUSCEPTIBILITY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIFUNGAL SUSCEPTIBILITY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIFUNGAL SUSCEPTIBILITY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIPARASITIC SUSCEPTIBILITY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIPARASITIC SUSCEPTIBILITY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIPARASITIC SUSCEPTIBILITY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIVIRAL SUSCEPTIBILITY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIVIRAL SUSCEPTIBILITY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIVIRAL SUSCEPTIBILITY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AGAR DILUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AGAR DILUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AGAR DILUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED AST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED AST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED AST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GENOTYPIC METHOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GENOTYPIC METHOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GENOTYPIC METHOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MACRODILUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MACRODILUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MACRODILUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ETEST METHOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ETEST METHOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ETEST METHOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY EPIDEMIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY EPIDEMIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY EPIDEMIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. GCC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. GCC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. GCC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 213. GCC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 214. GCC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 215. GCC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 216. GCC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. GCC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 218. GCC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 219. GCC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 220. GCC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 221. GCC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. G7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. G7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. G7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 249. G7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 250. G7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 251. G7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 252. G7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. G7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 254. G7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 255. G7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 256. G7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 257. G7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. NATO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. NATO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. NATO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 261. NATO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 262. NATO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 263. NATO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 264. NATO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. NATO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 266. NATO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 267. NATO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 268. NATO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 269. NATO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES A